Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

杜瓦卢马布 银耳霉素 吉西他滨 医学 内科学 顺铂 化疗 肿瘤科
作者
Do-Youn Oh,Kyung-Hun Lee,Dae-Won Lee,Jeesun Yoon,Tae-Yong Kim,Ju-Hee Bang,Ah-Rong Nam,Kyoung-Seok Oh,Jae-Min Kim,Young Lee,Violeta Guthrie,Patricia McCoon,Weimin Li,Song Wu,Qu Zhang,Marlon C Rebelatto,Jin Won Kim
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (6): 522-532
标识
DOI:10.1016/s2468-1253(22)00043-7
摘要

Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.This open-label, single-centre, phase 2 study was conducted at Seoul National University Hospital. Eligible patients were treatment-naïve adults aged 18 years or older with histologically proven unresectable or recurrent biliary tract cancer, at least one measurable lesion based on the Response Evaluation Criteria in Solid Tumors (version 1.1), an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 12 weeks or longer, and adequate healthy organ and bone marrow function. Initially, all patients received one 3-week cycle of gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) on day 1 and 8 followed by gemcitabine and cisplatin plus durvalumab (1120 mg) and tremelimumab (75 mg) on day 1 of each cycle, starting with the second cycle (chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group). Following protocol amendment, patients were recruited to receive gemcitabine and cisplatin plus durvalumab, starting on day 1 of the first cycle (chemotherapy plus durvalumab group) or gemcitabine and cisplatin plus durvalumab and tremelimumab also from day 1 of the first cycle (chemotherapy plus durvalumab and tremelimumab group) in parallel and allocated using a random block method. Assessors and patients were not masked to the treatment group. The primary endpoint was objective response rate, assessed in the efficacy population (ie, patients who were treated at least until the first tumour response assessment). This study is registered with ClinicalTrials.gov, NCT03046862 (active).Between March 2, 2017, and Feb 13, 2020, 128 patients were enrolled (32 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 49 in the chemotherapy plus durvalumab group, and 47 in the chemotherapy plus durvalumab and tremelimumab group). Four patients (two in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group and two in the chemotherapy plus durvalumab group) were excluded and 124 were evaluable for tumour response. The median duration of follow-up was 48·2 months (IQR 41·5-49·4) for the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 26·6 months (19·0-27·9) for the chemotherapy plus durvalumab group, and 24·2 months (20·7-31·7) for the chemotherapy plus durvalumab and tremelimumab group. 82 (66%) of 124 patients achieved an objective response (15 [50%] of 30 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 34 [72%] of 47 in the chemotherapy plus durvalumab group, and 33 [70%] of 47 in the chemotherapy plus durvalumab and tremelimumab group). The most common grade 3 and 4 adverse events were decreased neutrophil count (67 [53%] of 126), anaemia (50 [40%]), and decreased platelet count (24 [19%]), with no unexpected safety events. No adverse events leading to discontinuation or death occurred.Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with biliary tract cancer. Gemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study (NCT03875235) as first-line treatment in patients with advanced biliary tract cancer.AstraZeneca; National Research Foundation of Korea (Grant No. 2021R1A2C2007430).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
都是小儿卡通书完成签到,获得积分10
1秒前
2秒前
陶醉的又夏完成签到 ,获得积分10
2秒前
lily完成签到 ,获得积分10
5秒前
6秒前
子苓完成签到 ,获得积分10
8秒前
Jun完成签到 ,获得积分10
8秒前
phil完成签到,获得积分10
9秒前
祁乐安发布了新的文献求助20
9秒前
如初完成签到,获得积分10
10秒前
zzuwxj完成签到,获得积分10
13秒前
糊涂的语兰完成签到,获得积分10
17秒前
多余完成签到,获得积分10
18秒前
喝酸奶不舔盖完成签到 ,获得积分10
18秒前
朴实初夏完成签到 ,获得积分10
19秒前
19秒前
华仔应助查查make采纳,获得10
24秒前
乐乐应助普鲁卡因采纳,获得10
24秒前
美海与鱼完成签到,获得积分10
24秒前
哦豁完成签到 ,获得积分10
25秒前
阿钱小钱完成签到 ,获得积分10
26秒前
世上僅有的榮光之路完成签到,获得积分0
26秒前
能干的蜗牛完成签到,获得积分10
27秒前
芽衣完成签到 ,获得积分10
30秒前
31秒前
英姑应助大橙子采纳,获得10
34秒前
普鲁卡因发布了新的文献求助10
36秒前
积极的帽子完成签到 ,获得积分10
36秒前
量子星尘发布了新的文献求助10
38秒前
现代冷松完成签到,获得积分10
41秒前
Chimmy完成签到,获得积分10
46秒前
朴树朋友完成签到,获得积分20
46秒前
wlnhyF完成签到,获得积分10
48秒前
pursuit完成签到,获得积分10
51秒前
Neltharion完成签到,获得积分10
52秒前
沈海完成签到,获得积分10
54秒前
悦耳傥完成签到 ,获得积分10
54秒前
一叶知秋应助大橙子采纳,获得10
54秒前
科研小能手完成签到,获得积分10
55秒前
guoxingliu发布了新的文献求助200
56秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022